Radius Health to Announce Fourth Quarter and Full Year 2014 Financial Results, Host Conference Call and Live Webcast on March 10, 2015

WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2014 financial results on Tuesday, March 10, 2015.

In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on Tuesday, March 10, 2015 to discuss the results, and give an update on the Company's progress.

Conference Call Information:
: Tuesday, March 10, 2015
Time: 7:30 a.m. ET
Domestic Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Live webcast: http://public.viavid.com/player/index.php?id=113278

For those unable to participate in the conference call or live webcast, a replay will be available beginning March 10, 2015 at 10:30 a.m. ET until April 10, 2015 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176. The replay passcode is 13602238.

A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 30 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company's lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com.

CONTACT: Investor Relations Barbara Ryan Partner Clermont Partners 203-274-2825 bryan@radiuspharm.comSource:Radius Health